Literature DB >> 29529959

Impact of prolonged utilization of neprilysin inhibition on the cognitive function of heart failure patients.

Niel N Shah1, Muhammad U Dogar2, Parin N Shah3, Sameera Ishtiaq4, Shawn Mathew5, Pratik Shah6, Alia Ishtiaq7, Timothy J Vittorio8.   

Abstract

Entities:  

Year:  2018        PMID： 29529959      PMCID： PMC5941672          DOI： 10.1177/1753944718756563

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN： 1753-9447


× No keyword cloud information.
  35 in total

Review 1.  Metabolism of amyloid-beta peptide and Alzheimer's disease.

Authors:  Nobuhisa Iwata; Makoto Higuchi; Takaomi C Saido
Journal:  Pharmacol Ther       Date:  2005-08-19       Impact factor: 12.310

Review 2.  Neuroprotective effects of angiotensin receptor blockers.

Authors:  Sonia Villapol; Juan M Saavedra
Journal:  Am J Hypertens       Date:  2014-10-31       Impact factor: 2.689

3.  Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.

Authors:  Matthew L Hemming; Dennis J Selkoe; Wesley Farris
Journal:  Neurobiol Dis       Date:  2007-01-25       Impact factor: 5.996

4.  Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide.

Authors:  K Yasojima; H Akiyama; E G McGeer; P L McGeer
Journal:  Neurosci Lett       Date:  2001-01-12       Impact factor: 3.046

Review 5.  Do angiotensin receptor blockers prevent Alzheimer's disease?

Authors:  Ihab Hajjar; Kathleen Rodgers
Journal:  Curr Opin Cardiol       Date:  2013-07       Impact factor: 2.161

6.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

7.  Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide.

Authors:  Heidi T May; Benjamin D Horne; Wayne C Levy; Abdallah G Kfoury; Kismet D Rasmusson; David T Linker; Dariush Mozaffarian; Jeffrey L Anderson; Dale G Renlund
Journal:  Am J Cardiol       Date:  2007-06-26       Impact factor: 2.778

8.  Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

Authors:  Milton Packer; Robert M Califf; Marvin A Konstam; Henry Krum; John J McMurray; Jean-Lucien Rouleau; Karl Swedberg
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

9.  Long-term cognitive impairment after critical illness.

Authors:  P P Pandharipande; T D Girard; J C Jackson; A Morandi; J L Thompson; B T Pun; N E Brummel; C G Hughes; E E Vasilevskis; A K Shintani; K G Moons; S K Geevarghese; A Canonico; R O Hopkins; G R Bernard; R S Dittus; E W Ely
Journal:  N Engl J Med       Date:  2013-10-03       Impact factor: 91.245

10.  Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease.

Authors:  Carl I Webster; Matthew Burrell; Lise-Lotte Olsson; Susan B Fowler; Sarah Digby; Alan Sandercock; Arjan Snijder; Jan Tebbe; Ulrich Haupts; Joanna Grudzinska; Lutz Jermutus; Christin Andersson
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.